Semaglutide first came out in December 2017 as Ozempic. Learn when did semaglutide come out, how it was invented, how it is made, and key patent dates.
Semaglutide first came out in the United States in December 2017, when the FDA approved Ozempic injection for adults with type 2 diabetes. The oral form, Rybelsus, arrived in 2019, and the weight-management form, Wegovy, was approved in 2021. The molecule itself was invented years earlier, in the early 2000s, after researchers modified human GLP-1 to last longer in the body.
If you are asking when did semaglutide come out, the answer depends on which brand and formulation you mean. Ozempic, Rybelsus, and Wegovy all contain semaglutide, but they reached the market at different times and for different uses.
Semaglutide FDA Approval Timeline
Semaglutide's US rollout happened in stages. Each approval expanded the patient population or changed how the drug could be taken.
| Brand | Form | FDA approval | Initial use |
|---|---|---|---|
| Ozempic | Weekly injection | December 2017 | Type 2 diabetes |
| Rybelsus | Daily oral tablet | September 2019 | Type 2 diabetes |
| Wegovy | Weekly injection | June 2021 | Chronic weight management |
Ozempic was the first semaglutide product approved in the United States. Wegovy later became the first semaglutide product specifically approved for weight loss in adults with obesity or overweight with at least one weight-related condition.
When Was Semaglutide Invented?
Semaglutide was invented in the early 2000s by scientists at Novo Nordisk. It was not created as a completely new molecule from scratch; it was designed as a longer-acting version of earlier GLP-1 medicines, especially liraglutide.
Natural GLP-1 is a hormone that helps regulate blood sugar and appetite, but it breaks down quickly in the body. Researchers modified the peptide so it would resist breakdown by the DPP-4 enzyme and bind more tightly to albumin in the blood. That engineering made once-weekly dosing possible.
How Is Semaglutide Made?
Semaglutide is made through chemical peptide synthesis, not extracted from plants or animals. The process builds a 31-amino-acid peptide chain and then attaches a fatty acid side chain through a linker.
- Backbone modification: A key amino acid substitution helps the peptide resist enzymatic breakdown.
- Fatty acid side chain: The attached lipid chain lets semaglutide bind to albumin, extending its half-life.
- Oral formulation: Rybelsus pairs semaglutide with an absorption enhancer called SNAC to help it cross the stomach lining.
This engineering is why semaglutide can be given once weekly by injection or once daily by mouth, depending on the product. Manufacturing is tightly controlled because small changes in the peptide can affect purity, stability, and dosing.
Semaglutide Patent and Generic Availability
The core semaglutide patents were filed in the mid-2000s. In the United States, key patent protection is generally expected to last into the early 2030s, though the exact date depends on the patent, regulatory exclusivities, and any extensions.
Canada and some other countries may see generic or biosimilar competition sooner. Even after patents expire, a generic version must meet regulatory standards for quality and safety. Compounded semaglutide is not the same as FDA-approved semaglutide, and it is not reviewed by the FDA for safety, effectiveness, or quality.
Semaglutide is a prescription medicine, and it is not a cure for diabetes or obesity.
What Semaglutide Is Approved For Today
In the US, semaglutide products are approved for type 2 diabetes and chronic weight management, depending on the brand. Wegovy is approved for weight loss in adults with obesity or overweight with at least one weight-related condition, and for some adolescents. Ozempic and Rybelsus are approved for type 2 diabetes.
Some versions also have approvals to reduce cardiovascular risk in specific high-risk patients. These uses are prescription-only, and a healthcare professional should decide whether semaglutide is appropriate.
Common Questions and Related Research
People often ask does semaglutide make your hair fall out, especially after rapid weight loss or reduced food intake. Hair shedding can happen with any significant weight loss or nutritional deficiency, so it is worth discussing with a clinician if it occurs.
Researchers also study other metabolic peptides. Some compare aod 9604 and semaglutide, but they are different molecules with different mechanisms and regulatory status. Combination research includes cagrilintide and semaglutide, such as the CagriSema program, which pairs a GLP-1 with an amylin analog.
Timing questions like when to take aod 9604 morning or night apply to that peptide, not to semaglutide. Semaglutide dosing schedules are set by the product label and prescriber. Likewise, if you are exploring other peptides, you may wonder what happens when you stop taking cjc 1295; that is a separate topic from semaglutide's history and approval timeline.
Key Takeaways
- Semaglutide first came out in the US in December 2017 as Ozempic.
- Rybelsus was approved in 2019, and Wegovy was approved in 2021.
- The molecule was invented in the early 2000s and patented in the mid-2000s.
- Semaglutide is made by chemical peptide synthesis with a fatty acid side chain.
- Semaglutide is prescription-only, and safety should be discussed with a healthcare professional.
Frequently Asked Questions
When did semaglutide first come out in the US?
Semaglutide first came out in the US in December 2017, when the FDA approved Ozempic injection for type 2 diabetes. The oral form, Rybelsus, was approved in September 2019, and Wegovy was approved in June 2021 for chronic weight management.
When was semaglutide invented?
Semaglutide was invented in the early 2000s by researchers at Novo Nordisk. It was engineered from earlier GLP-1 research, including liraglutide, to create a longer-acting medicine that could be dosed less often.
Is semaglutide available as a generic in the US?
No FDA-approved generic semaglutide is currently available in the US. Key patents are generally expected to protect the brand products into the early 2030s, though timing can vary by patent, country, and regulatory exclusivity.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.